Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB4 | P30926 | 1/20 | 0.41 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.41 |
| ▸ | KDM1A | O60341 | 4/20 | 0.36 |
| ▸ | HTR2C | P28335 | 5/20 | 0.33 |
| ▸ | HTR2B | P41595 | 5/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 3/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7357341 | 0.77 | CHRNB4 (0.41) | CHRNB4CHRNA3KDM1AKDM1BCHRNB2 | |
| SCHEMBL18544377 | 0.74 | CHRNB4 (0.43) | CHRNB4CHRNA3KDM1AHTR2CHTR2B | |
| SCHEMBL14284253 | 0.73 | KDM1A (0.57) | KDM1AHTR2CHTR2BKDM1BHTR2A | |
| SCHEMBL5341308 | 0.73 | KDM1A (0.57) | KDM1AHTR2CHTR2BKDM1BHTR2A | |
| SCHEMBL7329321 | 0.73 | KDM1A (0.57) | KDM1AHTR2CHTR2BKDM1BHTR2A | |
| SCHEMBL10486425 | 0.73 | CHRNB4 (0.41) | CHRNB4CHRNA3KDM1AHTR2CHTR2B | |
| SCHEMBL7329314 | 0.73 | KDM1A (0.57) | KDM1AHTR2CHTR2BKDM1BHTR2A | |
| SCHEMBL5704636 | 0.73 | KDM1A (0.57) | KDM1AHTR2CHTR2BKDM1BHTR2A | |
| SCHEMBL6928599 | 0.73 | CHRNB4 (0.41) | CHRNB4CHRNA3KDM1AKDM1BCHRNB2 | |
| Hydrochloric Acid SCHEMBL11695201 | 0.71 | KDM1A (0.59) | KDM1AHTR2CKDM1BSLC6A2SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3215116-B1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIV OF THE SCIENCES IN PHILADELPHIA (US) | 2020-09-30 | — | — | EP | disclosed |
| US-10265413-B2 | High molecular weight biodegradable gelatin-doxorubicin conjugate | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2019-04-23 | — | — | US | disclosed |
| US-20170354741-A1 | HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2017-12-14 | — | — | US | disclosed |
| EP-3215116-A1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | University of the Sciences in Philadelphia (US) | 2017-09-13 | — | — | EP | disclosed |
| WO-2016077083-A1 | A HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | UNIVERSITY OF THE SCIENCES IN PHILADELPHIA (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20120196297-A1 | MASS TAGS FOR MASS SPECTROMETRIC ANALYSIS OF IMMUNOGLOBULINS | YOST RICHARD A (US) | 2012-08-02 | — | — | US | disclosed |
| WO-2011008831-A2 | MASS TAGS FOR SPECTROMETRIC ANALYSIS OF IMMUNOGLOBULINS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| US-7642344-B2 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES, INC. (US) | 2010-01-05 | — | — | US | disclosed |
| EP-0962537-B1 | Methods for analyzing nucleic acid molecules utilizing sizing techniques | OPERON BIOTECHNOLOGIES INC (US) | 2009-06-17 | — | — | EP | disclosed |
| EP-0992511-B1 | Methods and compositions for determining the sequence of nucleic acid molecules | OPERON BIOTECHNOLOGIES INC (US) | 2009-03-11 | — | — | EP | disclosed |
| EP-0962537-A2 | Methods and compositions for analyzing nucleic acid molecules utilizing sizing techniques | Rapigene, Inc. (US) | 1999-12-08 | — | — | EP | disclosed |
| WO-1999005319-A9 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE INC (US) | 1999-06-17 | — | — | WO | disclosed |
| WO-1999005319-A2 | METHODS AND COMPOUNDS FOR ANALYZING NUCLEIC ACIDS BY MASS SPECTROMETRY | RAPIGENE, INC. (US) | 1999-02-04 | — | — | WO | disclosed |
| EP-0868535-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | Rapigene, Inc. (US) | 1998-10-07 | — | — | EP | disclosed |
| EP-0850320-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | DARWIN MOLECULAR CORPORATION (US) | 1998-07-01 | — | — | EP | disclosed |
| EP-0840804-A1 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | DARWIN MOLECULAR CORPORATION (US) | 1998-05-13 | — | — | EP | disclosed |
| WO-1997027331-A9 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | — | 1997-10-09 | — | — | WO | disclosed |
| WO-1997027331-A2 | METHODS AND COMPOSITIONS FOR DETERMINING THE SEQUENCE OF NUCLEIC ACID MOLECULES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027325-A2 | METHODS AND COMPOSITIONS FOR ANALYZING NUCLEIC ACID MOLECULES UTILIZING SIZING TECHNIQUES | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
| WO-1997027327-A2 | METHODS AND COMPOSITIONS FOR DETECTING BINDING OF LIGAND PAIR USING NON-FLUORESCENT LABEL | RAPIGENE, INC. (US) | 1997-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170354741-A1 | HIGH MOLECULAR WEIGHT BIODEGRADABLE GELATIN-DOXORUBICIN CONJUGATE | MMP2, DNASE1L3, DNASE1 | CHRNB4 4671/4885CHRNA3 4640/4885KDM1A 2921/4885 |
| US-10265413-B2 | High molecular weight biodegradable gelatin-doxorubicin conjugate | MMP2, DNASE1L3, DNASE1 | CHRNB4 4671/4885CHRNA3 4640/4885KDM1A 2921/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.